Subtype
Ovarian Adenocarcinoma
CI-CAN-00006216Explore in graph →
83 active trials1 approved drugs8 evidence items
- NCIt
- C7700
Loading cancer entity…
Subtype
CI-CAN-00006216Explore in graph →
Clinical trials
183 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (25)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT06055348 | SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer | unknown | Phase 1 / Phase 2 | 112 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT00660101 |
| Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer |
| unknown |
| Phase 1 / Phase 2 |
| 34 |
| AVAX TechnologiesINDUSTRY |
| 1 |
| Dec 3, 2015 |
| clinicaltrials |
Data updated 23 days agoSource updated Oct 19, 2023source: clinicaltrials